Selected research
Industry Research
Mitogen Activated Protein Kinase 1 Industry Research Report 2026
Market perspective
The global Mitogen Activated Protein Kinase 1 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Mitogen Activated Protein Kinase 1 is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Mitogen Activated Protein Kinase 1 is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Mitogen Activated Protein Kinase 1 is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Mitogen Activated Protein Kinase 1 include Merck & Co., Inc., Merck KGaA, Laurent Pharmaceuticals Inc., Kura Oncology, Inc., Genentech, Inc., Asana BioSciences, LLC, AGV Discovery, SAS and Aeterna Zentaris Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Mitogen Activated Protein Kinase 1 market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mitogen Activated Protein Kinase 1 Market by Company
Merck & Co., Inc.
Merck KGaA
Laurent Pharmaceuticals Inc.
Kura Oncology, Inc.
Genentech, Inc.
Asana BioSciences, LLC
AGV Discovery, SAS
Aeterna Zentaris Inc.
Mitogen Activated Protein Kinase 1 Segment by Type
CB-745
JRP-890
KO-947
LY-3214996
Others
Mitogen Activated Protein Kinase 1 Segment by Application
Pancreatic Ductal Adenocarcinoma
Solid Tumor
Breast Cancer
Colon Cancer
Others
Mitogen Activated Protein Kinase 1 Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mitogen Activated Protein Kinase 1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mitogen Activated Protein Kinase 1 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mitogen Activated Protein Kinase 1.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Mitogen Activated Protein Kinase 1 manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Mitogen Activated Protein Kinase 1 by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Mitogen Activated Protein Kinase 1 in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- CB-745
- JRP-890
- KO-947
- LY-3214996
- Others
Applications
- Pancreatic Ductal Adenocarcinoma
- Solid Tumor
- Breast Cancer
- Colon Cancer
- Others
Companies covered
- Merck & Co., Inc.
- Merck KGaA
- Laurent Pharmaceuticals Inc.
- Kura Oncology, Inc.
- Genentech, Inc.
- Asana BioSciences, LLC
- AGV Discovery, SAS
- Aeterna Zentaris Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Mitogen Activated Protein Kinase 1 Market Size (2021-2032)
- 2.2.2 Global Mitogen Activated Protein Kinase 1 Sales (2021-2032)
- 2.2.3 Global Mitogen Activated Protein Kinase 1 Market Average Price (2021-2032)
- 2.3 Mitogen Activated Protein Kinase 1 by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 CB-745
- 2.3.3 JRP-890
- 2.3.4 KO-947
- 2.3.5 LY-3214996
- 2.3.6 Others
- 2.4 Mitogen Activated Protein Kinase 1 by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Pancreatic Ductal Adenocarcinoma
- 2.4.3 Solid Tumor
- 2.4.4 Breast Cancer
- 2.4.5 Colon Cancer
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Mitogen Activated Protein Kinase 1 Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Mitogen Activated Protein Kinase 1 Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Mitogen Activated Protein Kinase 1 Revenue of Manufacturers (2021-2026)
- 3.4 Global Mitogen Activated Protein Kinase 1 Average Price by Manufacturers (2021-2026)
- 3.5 Global Mitogen Activated Protein Kinase 1 Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Mitogen Activated Protein Kinase 1, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Mitogen Activated Protein Kinase 1, Product Type & Application
- 3.8 Global Manufacturers of Mitogen Activated Protein Kinase 1, Established Date
- 3.9 Global Mitogen Activated Protein Kinase 1 Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck & Co., Inc.
- 4.1.1 Merck & Co., Inc. Company Information
- 4.1.2 Merck & Co., Inc. Business Overview
- 4.1.3 Merck & Co., Inc. Mitogen Activated Protein Kinase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck & Co., Inc. Mitogen Activated Protein Kinase 1 Product Portfolio
- 4.1.5 Merck & Co., Inc. Recent Developments
- 4.2 Merck KGaA
- 4.2.1 Merck KGaA Company Information
- 4.2.2 Merck KGaA Business Overview
- 4.2.3 Merck KGaA Mitogen Activated Protein Kinase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck KGaA Mitogen Activated Protein Kinase 1 Product Portfolio
- 4.2.5 Merck KGaA Recent Developments
- 4.3 Laurent Pharmaceuticals Inc.
- 4.3.1 Laurent Pharmaceuticals Inc. Company Information
- 4.3.2 Laurent Pharmaceuticals Inc. Business Overview
- 4.3.3 Laurent Pharmaceuticals Inc. Mitogen Activated Protein Kinase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Laurent Pharmaceuticals Inc. Mitogen Activated Protein Kinase 1 Product Portfolio
- 4.3.5 Laurent Pharmaceuticals Inc. Recent Developments
- 4.4 Kura Oncology, Inc.
- 4.4.1 Kura Oncology, Inc. Company Information
- 4.4.2 Kura Oncology, Inc. Business Overview
- 4.4.3 Kura Oncology, Inc. Mitogen Activated Protein Kinase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Kura Oncology, Inc. Mitogen Activated Protein Kinase 1 Product Portfolio
- 4.4.5 Kura Oncology, Inc. Recent Developments
- 4.5 Genentech, Inc.
- 4.5.1 Genentech, Inc. Company Information
- 4.5.2 Genentech, Inc. Business Overview
- 4.5.3 Genentech, Inc. Mitogen Activated Protein Kinase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Genentech, Inc. Mitogen Activated Protein Kinase 1 Product Portfolio
- 4.5.5 Genentech, Inc. Recent Developments
- 4.6 Asana BioSciences, LLC
- 4.6.1 Asana BioSciences, LLC Company Information
- 4.6.2 Asana BioSciences, LLC Business Overview
- 4.6.3 Asana BioSciences, LLC Mitogen Activated Protein Kinase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Asana BioSciences, LLC Mitogen Activated Protein Kinase 1 Product Portfolio
- 4.6.5 Asana BioSciences, LLC Recent Developments
- 4.7 AGV Discovery, SAS
- 4.7.1 AGV Discovery, SAS Company Information
- 4.7.2 AGV Discovery, SAS Business Overview
- 4.7.3 AGV Discovery, SAS Mitogen Activated Protein Kinase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 AGV Discovery, SAS Mitogen Activated Protein Kinase 1 Product Portfolio
- 4.7.5 AGV Discovery, SAS Recent Developments
- 4.8 Aeterna Zentaris Inc.
- 4.8.1 Aeterna Zentaris Inc. Company Information
- 4.8.2 Aeterna Zentaris Inc. Business Overview
- 4.8.3 Aeterna Zentaris Inc. Mitogen Activated Protein Kinase 1 Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Aeterna Zentaris Inc. Mitogen Activated Protein Kinase 1 Product Portfolio
- 4.8.5 Aeterna Zentaris Inc. Recent Developments
5 Global Mitogen Activated Protein Kinase 1 Market Scenario by Region
- 5.1 Global Mitogen Activated Protein Kinase 1 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Mitogen Activated Protein Kinase 1 Sales by Region: 2021-2032
- 5.2.1 Global Mitogen Activated Protein Kinase 1 Sales by Region: 2021-2026
- 5.2.2 Global Mitogen Activated Protein Kinase 1 Sales by Region: 2027-2032
- 5.3 Global Mitogen Activated Protein Kinase 1 Revenue by Region: 2021-2032
- 5.3.1 Global Mitogen Activated Protein Kinase 1 Revenue by Region: 2021-2026
- 5.3.2 Global Mitogen Activated Protein Kinase 1 Revenue by Region: 2027-2032
- 5.4 North America Mitogen Activated Protein Kinase 1 Market Facts & Figures by Country
- 5.4.1 North America Mitogen Activated Protein Kinase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Mitogen Activated Protein Kinase 1 Sales by Country (2021-2032)
- 5.4.3 North America Mitogen Activated Protein Kinase 1 Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Mitogen Activated Protein Kinase 1 Market Facts & Figures by Country
- 5.5.1 Europe Mitogen Activated Protein Kinase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Mitogen Activated Protein Kinase 1 Sales by Country (2021-2032)
- 5.5.3 Europe Mitogen Activated Protein Kinase 1 Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Mitogen Activated Protein Kinase 1 Market Facts & Figures by Country
- 5.6.1 Asia Pacific Mitogen Activated Protein Kinase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Mitogen Activated Protein Kinase 1 Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Mitogen Activated Protein Kinase 1 Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Mitogen Activated Protein Kinase 1 Market Facts & Figures by Country
- 5.7.1 South America Mitogen Activated Protein Kinase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Mitogen Activated Protein Kinase 1 Sales by Country (2021-2032)
- 5.7.3 South America Mitogen Activated Protein Kinase 1 Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Mitogen Activated Protein Kinase 1 Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Mitogen Activated Protein Kinase 1 Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Mitogen Activated Protein Kinase 1 Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Mitogen Activated Protein Kinase 1 Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Mitogen Activated Protein Kinase 1 Sales by Type (2021-2032)
- 6.1.1 Global Mitogen Activated Protein Kinase 1 Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Mitogen Activated Protein Kinase 1 Sales Market Share by Type (2021-2032)
- 6.2 Global Mitogen Activated Protein Kinase 1 Revenue by Type (2021-2032)
- 6.2.1 Global Mitogen Activated Protein Kinase 1 Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Mitogen Activated Protein Kinase 1 Revenue Market Share by Type (2021-2032)
- 6.3 Global Mitogen Activated Protein Kinase 1 Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Mitogen Activated Protein Kinase 1 Sales by Application (2021-2032)
- 7.1.1 Global Mitogen Activated Protein Kinase 1 Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Mitogen Activated Protein Kinase 1 Sales Market Share by Application (2021-2032)
- 7.2 Global Mitogen Activated Protein Kinase 1 Revenue by Application (2021-2032)
- 7.2.1 Global Mitogen Activated Protein Kinase 1 Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Mitogen Activated Protein Kinase 1 Revenue Market Share by Application (2021-2032)
- 7.3 Global Mitogen Activated Protein Kinase 1 Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Mitogen Activated Protein Kinase 1 Value Chain Analysis
- 8.1.1 Mitogen Activated Protein Kinase 1 Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Mitogen Activated Protein Kinase 1 Production Mode & Process
- 8.2 Mitogen Activated Protein Kinase 1 Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Mitogen Activated Protein Kinase 1 Distributors
- 8.2.3 Mitogen Activated Protein Kinase 1 Customers
9 Global Mitogen Activated Protein Kinase 1 Analyzing Market Dynamics
- 9.1 Mitogen Activated Protein Kinase 1 Industry Trends
- 9.2 Mitogen Activated Protein Kinase 1 Industry Drivers
- 9.3 Mitogen Activated Protein Kinase 1 Industry Opportunities and Challenges
- 9.4 Mitogen Activated Protein Kinase 1 Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst